Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

• ClinicalTrials.gov Identifier: NCT03173248
• Recruitment Status: Active, not recruiting
• First Posted: June 1, 2017
• Results First Posted: March 23, 2023
• Last Update Posted: April 5, 2024
• Sponsor: Institut de Recherches Internationales Servier
• Information provided by (Responsible Party): Servier ( Institut de Recherches Internationales Servier )

Study Description

Brief Summary:

Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib) + azacitidine vs placebo + azacitidine in adult participants with previously untreated IDH1m AML who are considered appropriate candidates for non-intensive therapy. The primary endpoint is event-free survival (EFS). The key secondary efficacy endpoints are overall survival (OS), rate of complete remission (CR), rate of CR and complete remission with partial hematologic recovery (CRh), and overall response rate (ORR). Participants eligible for study treatment based on Screening assessments will be randomized 1:1 to receive oral AG-120 or matched placebo, both administered in combination with subcutaneous (SC) or intravenous (IV) azacitidine. An estimated 200 participants will take part in the study.

Condition or disease	Intervention/treatment	Phase
Newly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS); Leukemia, Myeloid, Acute	Drug: AG-120; Drug: Placebo; Drug: Azacitidine	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 146 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
• Actual Study Start Date: June 26, 2017
• Actual Primary Completion Date: March 18, 2021
• Estimated Study Completion Date: June 30, 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: AG-120 + Azacitidine; Participants received AG-120 500 mg orally, once daily (QD) in combination with azacitidine 75 milligrams per square meter per day (mg/m^2/day) subcutaneously (SC) or intravenously (IV), on Days 1-7, or on Days 1-5 and 8-9, of each 28-day cycle for a minimum of 6 cycles until death, disease relapse, disease progression, development of unacceptable toxicity (adverse event), confirmed pregnancy, withdrawal by participant or protocol violation.	Drug: AG-120; Tablets administered orally; Other Name: Ivosidenib; Drug: Azacitidine; Administered SC or IV; Other Name: Vidaza®
Placebo Comparator: Placebo + Azacitidine; Participants received AG-120 matching placebo orally, QD in combination with azacitidine 75 mg/m^2/day SC or IV, on Days 1-7, or on Days 1-5 and 8-9, of each 28-day cycle for a minimum of 6 cycles until death, disease relapse, disease progression, development of unacceptable toxicity (adverse event), confirmed pregnancy, withdrawal by participant or protocol violation .	Drug: Placebo; Tablets administered orally; Drug: Azacitidine; Administered SC or IV; Other Name: Vidaza®

Outcome Measures

Primary Outcome Measures :

1. Event-Free Survival (EFS) [ Time Frame: Up to Week 24 ]
   EFS was defined as the time from randomization until treatment failure, relapse from remission, or death from any cause, whichever occurs first. Treatment failure was defined as failure to achieve complete remission (CR) by Week 24. CR: Bone marrow blasts <5% and no Auer rods; absence of extramedullary disease; Absolute neutrophil count (ANC) ≥1.0 × 10^9 per litre (10^9/L) (1000 per microlitre [1000/μL]); platelet count ≥100 × 10^9/L (100,000/μL); independence of red blood cell transfusions. Participants who had an EFS event (relapse or death) after, 2 or more missing disease assessments were censored at the last adequate disease assessment documenting no relapse before the missing assessments. The reported data represents the Kaplan-Meier median value.

Secondary Outcome Measures :

1. Complete Remission Rate (CR Rate) [ Time Frame: Up to approximately 52 months ]
   CR rate is defined as the proportion of participants who achieve a CR. A Cochran-Mantel-Haenszel (CMH) test will be used to compare CR rate between the 2 treatment arms.
2. Overall Survival (OS) [ Time Frame: Up to approximately 52 months ]
   OS is defined as the time from date of randomization to the date of death due to any cause. Kaplan-Meier (KM) curves and KM estimates of OS will be presented for each treatment arm.
3. CR + Complete Remission With Partial Hematologic (CRh) Rate [ Time Frame: Up to approximately 52 months ]
   CR + CRh rate is defined as the proportion of participants who achieve a CR or CRh. CRh is defined as a CR with partial recovery of peripheral blood counts (less than 5% bone marrow blasts, absolute neutrophil count (ANC) greater than 0.5 × 10^9/liter (L) 500/microliter (μL)], and platelets greater than 50 × 10^9/L [50,000/μL]). A CMH test will be used to compare the CR + CRh rate between the 2 treatment arms.
4. Objective Response Rate (ORR) [ Time Frame: Up to approximately 52 months ]
   ORR is defined as the rate of CR, CR with incomplete hematologic recovery (CRi) (including CR with incomplete platelet recovery [CRp]), partial remission (PR), and morphologic leukemia-free state (MLFS). The best response is calculated using the following hierarchy: CR, followed by CRi (including CRp), followed by PR and MLFS. A summary of best response by treatment arm will be produced. A CMH test will be used to compare ORR between the 2 treatment arms.
5. CR + CRi (Including CRp) Rate [ Time Frame: Up to approximately 52 months ]
   The CR + CRi (including CRp) rate is defined as the proportion of participants who achieve a CR or CRi (including CRp). A CMH test will be used to compare the CR + CRi (including CRp) rate between the 2 treatment arms.
6. Duration of CR (DOCR) [ Time Frame: Up to approximately 52 months ]
   DOCR will be calculated as the date of the first occurrence of CR to the date of first documented disease relapse, or death. DOCR is only defined for participants who achieve a CR.
7. Duration of CRh (DOCRh) [ Time Frame: Up to approximately 52 months ]
   DOCRh will be calculated as the date of the first occurrence of CR or CRh to the date of first documented disease relapse or death. DOCRh is only defined for participants who achieve a CR or CRh.
8. Duration of Response (DOR) [ Time Frame: Up to approximately 52 months ]
   DOR will be calculated as the date of the first response to the date of first documented disease relapse, disease progression, or death. DOR is only defined for participants who achieve a CR, CRi (including CRp), PR, and/or MLFS.
9. Duration of CRi (DOCRi) [ Time Frame: Up to approximately 52 months ]
   DOCRi will be calculated as the date of the first occurrence of CR or CRi (including CRp) to the date of the first documented relapse or death. DOCRi is only defined for participants who achieve a CR or CRi (including CRp).
10. Time to CR (TTCR) [ Time Frame: Up to approximately 52 months ]
    TTCR will be assessed from the date of randomization to the date of first occurrence of CR. TTCR is only defined for participants who achieve a CR.
11. Time to CRh (TTCRh) [ Time Frame: Up to approximately 52 months ]
    TTCRh will be assessed from the date of randomization to the date of first occurrence of CR or CRh. TTCRh is only defined for participants who achieve a CR or CRh.
12. Time to Response (TTR) [ Time Frame: Up to approximately 52 months ]
    TTR will be assessed from the date of randomization to the date of the first response. TTR is only defined for participants who achieve a CR, CRi (including CRp), PR, and/or MLFS.
13. Time to CRi (TTCRi) [ Time Frame: Up to approximately 52 months ]
    TTCRi will be assessed from the date of randomization to the date of first occurrence of CR or CRi (including CRp). TTCRi is only defined for participants who achieve a CR or CRi (including CRp).
14. Percentage of Participants With Abnormalities in Vital Sign Measurements [ Time Frame: Up to approximately 52 months ]
    Vital signs will include body temperature, respiratory rate, blood pressure, and heart rate.
15. Percentage of Participants With Abnormalities in Eastern Cooperative Oncology Group Performance Status (ECOG PS) [ Time Frame: Up to approximately 52 months ]
16. Percentage of Participants With Abnormalities in 12-lead Electrocardiograms (ECGs) [ Time Frame: Up to approximately 52 months ]
17. Percentage of Participants With Abnormalities in Echocardiogram (ECHO) or Multi-Gated Acquisition (MUGA) for Left Ventricular Ejection Fraction (LVEF) [ Time Frame: Up to approximately 52 months ]
    LVEF is determined by ECHO or MUGA scan in participants.
18. Percentage of Participants With Abnormalities in Clinical Laboratory Tests [ Time Frame: Up to approximately 52 months ]
    Clinical laboratory assessments will include hematology, serum chemistry, coagulation.
19. Percentage of Participants With Adverse Events (AEs) [ Time Frame: Up to approximately 52 months ]
    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.
20. Percentage of Participants With AEs of Special Interest (AESIs) [ Time Frame: Up to approximately 52 months ]
    AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESIs include protocol-specified QT prolongation, isocitrate dehydrogenase (IDH) differentiation syndrome and leukocytosis.
21. Percentage of Participants With Serious Adverse Events (SAEs) [ Time Frame: Up to approximately 52 months ]
    An SAE is defined as an untoward medical occurrence, significant hazard, contraindication, side effect or precaution that at any dose: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
22. Percentage of Participants With Adverse Events Leading to Discontinuation or Death [ Time Frame: Up to approximately 52 months ]
    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.
23. Percentage of Participants Using Concomitant Medications [ Time Frame: Up to approximately 52 months ]
    Participants receiving concomitant medications will be adequately monitored by ECG controls, drug concentration (where applicable), and serum electrolytes (i.e., potassium and magnesium).
24. Units of Platelets and Red Blood Cells (RBC) Infused [ Time Frame: Up to approximately 52 months ]
    All measures that are indicative of clinical benefit are measured like number of units of platelet and RBC infused.
25. Rate of Infection [ Time Frame: Up to approximately 52 months ]
26. Number of Days Spent Hospitalized [ Time Frame: Up to approximately 52 months ]
27. Change From Baseline in the European Organisation for Research and Treatment of Cancer (EORTC) QLC-C30 Questionnaire [ Time Frame: Up to approximately 52 months ]
    The EORTC QLQ-C30 questionnaire measures quality of life and consists of 30 questions that are incorporated into 5 functional domains (physical, role, cognitive, emotional, and social); a global health status/global quality of life; 3 symptom scales (fatigue, pain, and nausea and vomiting); and 6 single items that assess additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and the perceived financial burden of treatment experienced by participants with cancer.
28. Change From Baseline in the EORTC EQ-5D-5L Questionnaire [ Time Frame: Up to approximately 52 months ]
    The EORTC EQ-5D-5L questionnaire measures quality of life and spans 5 dimensions, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, which are used to build a composite of the participant's health status.
29. Percentage of Participants With CR With IDH1 Mutation Clearance (MC) [ Time Frame: Up to approximately 52 months ]
    CR with IDH1 MC is defined as a response of CR where there is no evidence of the IDH1 mutation by molecular techniques to below the level of detection (0.02%-0.04%) for ≥1 on-treatment time point. A CMH test will be used to compare the rate of CR between 2 treatment arms.
30. Percentage of Participants With Drug Exposure, Dose Modifications and Dose Intensities [ Time Frame: Up to approximately 52 months ]
    The number of doses administered, total dose, duration of treatment, dose intensity, and the proportion of participants with dose modifications, will be summarized by treatment arm.
31. Circulating Plasma Concentration of AG-120 [ Time Frame: Up to approximately 52 months ]
    Serial blood samples will be drawn before and after dosing of study treatment in order to determine circulating plasma concentrations.
32. Circulating Plasma Concentration of 2-HG [ Time Frame: Up to approximately 52 months ]
    Serial blood samples will be drawn before and after dosing of study treatment in order to determine circulating plasma concentrations.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Be ≥ 18 years of age and meet at least 1 of the following criteria defining ineligibility for intensive induction chemotherapy (IC): ≥ 75 years old, Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 2, severe cardiac disorder (e.g., congestive heart failure requiring treatment, left ventricular ejection fraction (LVEF), ≤50%, or chronic stable angina), severe pulmonary disorder (e.g., diffusing capacity of the lungs for carbon monoxide ≤65% or forced expiratory volume in 1 second ≤65%), creatinine clearance <45 mL/minute, bilirubin >1.5 times the upper limit of normal (ULN) and/or have any other comorbidity that the Investigator judges to be incompatible with intensive IC and must be reviewed and approved by the Medical Monitor before study enrollment.
2. Have previously untreated AML, defined according to World Health Organization (WHO) criteria, with ≥ 20% leukemic blasts in the bone marrow. Participants with extramedullary disease alone (i.e., no detectable bone marrow and no detectable peripheral blood AML) are not eligible for the study.
3. Have an isocitrate dehydrogenase 1 (IDH1) mutation.
4. Have an ECOG PS score of 0 to 2.
5. Have adequate hepatic function.
6. Have adequate renal function.
7. Have agreed to undergo serial blood and bone marrow sampling.
8. Be able to understand and willing to sign an informed consent form (ICF).
9. Be willing to complete Quality of Life assessments during the study
10. If female with reproductive potential, must have a negative serum pregnancy test prior to the start of study therapy. Females of reproductive potential, as well as fertile men and their female partners of reproductive potential, must agree to use 2 effective forms of contraception.

Exclusion Criteria:

1. Are candidates for and willing to receive intensive induction chemotherapy (IC) for their AML.
2. Have received any prior treatment for AML with the exception of hydroxyurea.
3. Have received a hypomethylating agent for myelodysplastic syndrome (MDS).
4. Participants who had previously received an experimental agent for MDS may not be randomized until a washout period has elapsed since the last dose of that agent.
5. Have received prior treatment with an IDH1 inhibitor.
6. Have a known hypersensitivity to any of the components of AG-120, matched placebo, or azacitidine.
7. Are female and pregnant or breastfeeding.
8. Have an active, uncontrolled, systemic fungal, bacterial, or viral infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.
9. Have a prior history of cancer other than MDS or myeloproliferative disorder, unless the participant has been free of the disease for ≥ 1 year prior to the start of study treatment.
10. Have had significant active cardiac disease within 6 months prior to the start of the study treatment.
11. Have any condition that increases the risk of abnormal ECG or cardiac arrhythmia.
12. Have a condition that limits the ingestion or absorption of drugs administered by mouth.
13. Have uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or diastolic BP > 100 mmHg).
14. Have clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia.
15. Have immediate, life-threatening, severe complications of leukemia, such as uncontrolled bleeding, pneumonia with hypoxia or sepsis, and/or disseminated intravascular coagulation.
16. Have any other medical or psychological condition deemed by the Investigator to be likely to interfere with the participant's ability to give informed consent or participate in the study.
17. Are taking medications that are known to prolong the QT interval unless they can be transferred to other medications within ≥5 half-lives prior to dosing, or unless the medications can be properly monitored during the study. (If equivalent medication is not available, heart rate corrected QT interval [QTc] will be closely monitored.)
18. Have a known medical history of progressive multifocal leukoencephalopathy.

Contacts and Locations

Locations

United States, Kentucky

Norton Cancer Institute - Suburban

Louisville, Kentucky, United States, 40207

United States, Massachusetts

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Australia, New South Wales

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia, 2050

Australia, South Australia

Royal Adelaide Hospital

Adelaide, South Australia, Australia, 5000

Flinders Medical Centre

Bedford park, South Australia, Australia, 5042

Austria

Salzburger Landeskliniken

Salzburg, Austria, 5020

Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhugel

Wien, Austria, 1130

Brazil

Unicamp Universidade Estadual de Campinas

Campinas, Sao Paulo, Brazil, 13083-878

Hospital Amaral Carvalho

Jau, Sao Paulo, Brazil, 17210-120

Instituto Nacional de Cancer

Rio De Janeiro, Brazil, 20230-130

Hospital Sirio Libanes

Sao Paulo, Brazil, 01308-050

Hospital Sao Jose

Sao Paulo, Brazil, 01321-001

Hospital Santa Marcelina

Sao Paulo, Brazil, 08270-070

Canada, Manitoba

Cancer Care Manitoba

Winnipeg, Manitoba, Canada, R3E 0V9

Canada, Ontario

University Health Network

Toronto, Ontario, Canada, M5G 2M9

China, Henan

Henan Cancer Hospital

Zhengzhou, Henan, China, 450008

China, Sichuan

West China Hospital Sichuan University

Chengdu, Sichuan, China, 610041

China

Peking Union Medical College Hospital

Beijing, China

Guangdong Provincial People's Hospital

Guangzhou, China, 510080

The First Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, China, 310003

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences

Tianjin, China, 300020

Czechia

Fakultni nemocnice Ostrava

Ostrava, Czechia

France

Hopital Haut Leveque

Pessac, Gironde, France, 33604

Hopital Bretonneau

Tours, Indre-et-Loire, France, 37044

Hotel Dieu - Nantes

Nantes, Loire-Atlantique, France, 44093

Centre Hospitalier Lyon Sud

Pierre-benite, Rhone, France, 69495

Centre Hospitalier Le Mans

Le Mans, Sarthe, France, 72037

CHRU de Brest - Hopital Morvan

Brest, France, 29609

Institut dHematologie de Basse Normandie

Caen, France, 14000

CHU de Grenoble

Grenoble, France, 38043

Centre Hospitalier de Versailles CHV Hopital Andre Mignot

Le Chesnay, France, 78 157

Groupe Hospitalier Necker Enfants Malades

Paris, France, 75015

CHRU de Poitiers La Miletrie

Poitiers, France, 86021

Hopital de Hautepierre

Strasbourg, France, 67200

EDOG - Institut Claudius Regaud - PPDS

Toulouse, France, 31059

Institut Gustave Roussy

Villejuif, France, 94805

Germany

Universitatsklinikum Essen

Essen, Nordrhein-Westfalen, Germany, 45122

Klinikum Chemnitz gGmbH

Chemnitz, Sachsen, Germany, 09113

Charite - Universitatsmedizin Berlin

Berlin, Germany, 13353

Medizinische Hochschule Hannover

Hannover, Germany, 30625

Universitatsklinikum Leipzig

Leipzig, Germany, 04103

LMU Klinikum der Universitat Munchen

Munchen, Germany, 81377

Universitatsklinikum Ulm

Ulm, Germany, 89081

Israel

Rabin Medical Center - PPDS

Petah Tikva, Israel, 49100

Kaplan Medical Center

Rehovot, Israel, 7610000

Italy

ASST dei Sette Laghi - Ospedale Di Circolo E Fondazione Macchi

Varese, Lombardia, Italy, 21100

Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS

Meldola, Italy, 47014

Ospedale San Raffaele S.r.l. - PPDS

Milano, Italy, 20132

ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda

Milano, Italy, 20162

Fondazione IRCCS Policlinico San Matteo di Pavia

Pavia, Italy, 27100

Ospedale Infermi di Rimini

Rimini, Italy, 47900

Azienda Ospedaliera Citta della Salute e della Scienza di Torino

Torino, Italy, 10126

Japan

Matsuyama Red Cross Hospital

Matsuyama, Ehime, Japan, 790-8524

University of Fukui Hospital

Fukui, Japan, 910-1193

Japanese Red Cross Society Himeji Hospital

Himeji, Japan, 670-8540

Kobe City Medical Center General Hospital

Kobe, Japan

Korea, Republic of

National Cancer Center

Goyang-si, Gyeonggido, Korea, Republic of, 10408

Ajou University Hospital

Suwon-si, Gyeonggido, Korea, Republic of, 16499

Pusan National University Hospital

Busan, Korea, Republic of, 602-739

Severance Hospital Yonsei University Health System

Seoul, Korea, Republic of, 03722

Seoul National University Hospital

Seoul, Korea, Republic of, 110-744

Mexico

SINACOR

Culiacan, Mexico, 80230

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Mexico, Mexico, 14000

Netherlands

VU Medisch Centrum

Amsterdam, Noord-Holland, Netherlands, 1081 HV

Universitair Medisch Centrum Groningen

Nijmegen, Netherlands, 6525 GA

Poland

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu

Wroclaw, Dolnoslaskie, Poland, 50-367

Instytut Hematologii i Transfuzjologii

Warszawa, Mazowieckie, Poland, 02-776

Uniwersyteckie Centrum Kliniczne

Gdansk, Poland, 80-214

Russian Federation

Kaluga Regional Clinical Hospital

Kaluga, Russian Federation, 248007

City Clinical Hospital # 40

Moscow, Russian Federation, 129301

Spain

CHUS H. Clinico U. de Santiago

Santiago de Compostela, A Coruna, Spain, 15706

Hospital Universitario Son Espases

Palma de Mallorca, Baleares, Spain, 07010

Hospital Universitario Germans Trias i Pujol

Badalona, Barcelona, Spain, 08916

Hospital Universitario de Gran Canaria Doctor Negrin

Las Palmas de Gran Canaria, Las Palmas, Spain, 35010

Hospital Universitario Vall d'Hebron - PPDS

Barcelona, Spain, 08035

Hospital Clinic de Barcelona

Barcelona, Spain, 08036

Hospital General Universitario Gregorio Maranon

Madrid, Spain, 28007

Hospital Universitario Ramon y Cajal

Madrid, Spain, 28034

Hospital Universitario Fundacion Jimenez Diaz

Madrid, Spain, 28040

Hospital Universitario 12 de Octubre

Madrid, Spain, 28041

Hospital Universitario Virgen del Rocio - PPDS

Sevilla, Spain, 41013

Hospital Universitari i Politecnic La Fe de Valencia

Valencia, Spain, 46026

Hospital Clinico Universitario Lozano Blesa

Zaragoza, Spain, 50009

Taiwan

Changhua Christian Medical Foundation Changhua Christian Hospital

Changhua City, Taiwan, 500

Kaohsiung Medical University Hospital

Kaohsiung, Taiwan, 807

China Medical University Hospital

Taichung City, Taiwan, 40447

Chi Mei Medical Center, Liouying

Tainan City, Taiwan, 736

National Taiwan University Hospital

Taipei, Taiwan

United Kingdom

Birmingham Heartlands Hospital

Birmingham, West Midlands, United Kingdom, B9 5SS

Sponsors and Collaborators

Institut de Recherches Internationales Servier

  Study Documents (Full-Text)

Documents provided by Servier ( Institut de Recherches Internationales Servier ):

Study Protocol  [PDF] October 7, 2021

Statistical Analysis Plan  [PDF] June 23, 2020

More Information

Study Data/Documents: Individual Participant Data Set 

Study Protocol 

Statistical Analysis Plan 

Informed Consent Form 

Clinical Study Report 

Study-level clinical trial data 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Dohner H. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med. 2022 Apr 21;386(16):1519-1531. doi: 10.1056/NEJMoa2117344.

• Responsible Party: Institut de Recherches Internationales Servier
• ClinicalTrials.gov Identifier: NCT03173248
• Other Study ID Numbers: AG120-C-009
• First Posted: June 1, 2017
• Results First Posted: March 23, 2023
• Last Update Posted: April 5, 2024
• Last Verified: April 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

Plan Description

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

• used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
• where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

• sponsored by Servier
• with a first patient enrolled as of 1 January 2004 onwards
• for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR)
• Time Frame: After Marketing Authorisation in EEA or US if the study is used for the approval.
• Access Criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
• URL: https://clinicaltrials.servier.com/

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Servier ( Institut de Recherches Internationales Servier ):

Acute Myeloid Leukemia; Leukemia; Azacitidine; AG-120; ivosidenib

Additional relevant MeSH terms:

Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Myelodysplastic Syndromes; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Bone Marrow Diseases; Precancerous Conditions; Azacitidine; Ivosidenib; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Enzyme Inhibitors